Loading...
$119.2M
Awarded Apr 6, 2026
Competition
FULL AND OPEN COMPETITION
Offers
1
Set-Aside
None
Solicitation Type
RFP - Negotiated
Performance Timeline
Start
Apr 6, 2026
Estimated start: Mar 10, 2035
Contract: 75A50126C00004
UEI
V8H8DT6RCHW6
Parent Company
SHIONOGI & COMPANY LIMITED
Capabilities & Certifications
Headquarters Location
Congressional District: 11
Current Obligation
$119,160,691
Base + Exercised Options
$119,160,691
Total Ceiling Value
$481,678,318
Contract Type
COST PLUS FIXED FEE
Multi-Year Contract
NO
Description
LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
Place of Performance
Congressional District: 11
Awarding Agency
Top-tier Agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier Agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Funding Agency
Top-tier Agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier Agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office